An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.